Main Catalog

AMCP Web Site

Main Catalog

Found 95

Sort By

Member Free

Non-Member Free

AMCP 2021 Virtual

AMCP is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education (CPE).

All CPE sessions at AMCP 2021 are knowledge-based and designed primarily for pharmacists to acquire factual knowledge.

AMCP 2021 Virtual

Member Free

Non-Member Free

The Evidence Behind COVID-19 Treatments and Vaccines - Home Study

Contact Hours: 1.0 - COVID-19 has caused significant social and economic disruptions around the world.

COVID19

Member $800.00

Non-Member $800.00

Medical Benefits Training

AMCP’s Medical Benefit Medication Management is an 8-part series built specifically for members of Life Science companies.

Medical Benefits Training

Member Free

Non-Member $30.00

Visions of a US Value-Based Health Care System

Contact Hours: 1.25. Value—a word of great promise and ambiguity—continues to chisel and sculpt the national health care system at large.

Hospital/Health Systems

Member Free

Non-Member $30.00

Using Online Real-World Evidence Tools to Enhance Formulary Decision-Making - Nexus 2018

Contact Hours: 1.5. Evidence to determine comparative effectiveness and safety requires the use of real-world data (RWD) to create real-world evidence (RWE) that ultimately is used to inform policy decisions.

Real-World Evidence

Member $15.00

Non-Member $30.00

The Present and Future of Hemophilia Treatment - Annual Meeting 2018

Contact Hours: 1 - Over the past few decades, the treatment of hemophilia has been transformed by the emergence of safer clotting factor replacement products, and the growing use of prophylactic therapy to prevent bleeding and joint destruction.

Hemophilia

Member Free

Non-Member $30.00

The Current State of Value-Based Contracting

Contact Hours 1.25. Value-based contracting (VBC) has shown significant promise as an emerging model that rewards value rather than volume in health care.

Value-Based Contracting

Member Free

Non-Member $30.00

The Copay Card Conundrum: Examining the Usage, Regulation, and Management of Direct-to-Consumer Funding Programs

Contact Hours: 1.25. Drug manufacturer copay cards and coupons have been facing increasing criticism and scrutiny by legislators at the federal and state level, as well as by health plan payers, pharmacy benefit managers (PBMs) and employer groups.

Copay Cards

Member Free

Non-Member $30.00

The CAR-T Carve-Out: Reevaluating CAR-T Reimbursement and Long Term Outcomes - Nexus 2018

Contact Hours: 1.5. The CAR-T treatment process is complex and involves a multidisciplinary team, with intense coordination between patients, treating providers, manufacturers and payers.

Hospital/Health Systems

Member Free

Non-Member $30.00

Strategies for Staying Ahead of Specialty Drug Trends: Focus on the Medical Pharmacy Benefit

Contact Hours 1.25. For the tenth consecutive year, specialty pharmaceutical growth has far exceeded that of traditional drugs.

Specialty

Member Free

Non-Member $30.00

Specialty Pharmaceuticals in Development - Nexus 2018

Contact Hours: 1.25. Over the last several years, approvals of specialty pharmaceuticals have far outpaced those of traditional drugs. It is anticipated that this trend will continue.

Specialty

Member Free

Non-Member $30.00

Real-World Experience Managing Orphan Drugs Across Pharmacy and Medical Benefits

Contact Hours: 1.25. Recently approved drugs for orphan diseases have annual costs ranging from $90,000 to over $1 million, while also having variable value propositions.

Orphan Disease

Member Free

Non-Member $30.00

Pulmonary Arterial Hypertension and the Managed Care Considerations for Formulary Decision-Making

Contact Hours: 1.25. Patients with pulmonary arterial hypertension (PAH) currently have a 60% five-year survival outlook, which has been increasing since the 1980s when it was a 37% five-year outlook.

Pulmonary Arterial Hypertension

Member Free

Non-Member Free

Navigating Changes in Clostridioides difficile Prevention and Treatment - Home Study

Contact Hours: 1. 5 - Clostridioides difficile (C. diff, previously known as Clostridium difficile) infections are a major health care concern.

C. Diff

Member Free

Non-Member $30.00

More than Meets the Eye–Value-Based Contracts are More Prevalent than We Think

Contact Hours: 1.25. As the U.S. health care system evolves from a volume-driven system to one that rewards value, there is growing interest in value-based payment arrangements.

Value-Based Contracting

Member Free

Non-Member $30.00

Medicare Formulary Updates Impact

Contact Hours: 1.25. The Centers for Medicare and Medicaid (CMS) continues to critically evaluate formulary regulations and guidance to help lower drug costs.

Medicare

Member Free

Non-Member $30.00

Digital Therapeutics: Understanding the Emerging Product Class Home Study

Contact Hours: 1 - Digital therapeutics (DTx) are emerging as a novel treatment modality for a wide range of health conditions, either as stand-alone products or for use in conjunction with other treatments.

Digital Health AMCP eLearning Days

Member Free

Non-Member $30.00

Measuring Value of an IDN Specialty Pharmacy Therapy Management Program for Biologics

Contact Hours: 1.25: Gene therapy is a promising treatment option for a number of diseases, including inherited disorders, some types of cancer, and certain viral infections. The first gene therapy approvals in the United States occurred in 2017.

Specialty

Member Free

Non-Member $30.00

Key Forces Driving Change in Oncology

Contact Hours: 1.25. Oncology practice is changing rapidly as new advances in innovation lead to new evidence and testing requirements, as well as treatment guidelines.

Oncology

Member Free

Non-Member $30.00

It’s an ART: Formulary and Drug Use Management Strategies for HIV Medications - Annual 2019

Contact Hours: 1.25. As people with HIV age, the focus of disease management places more emphasis on the safety of long-term medication use and managing comorbidities. The advantages of safer, more efficacious medications also come with increased cost.

HIV

Member $15.00

Non-Member $30.00

Introduction to Gene Therapy: Key Terms, Concepts, and International Perspectives - Annual Meeting 2019

Contact Hours: 1 - Gene therapy is an investigational technique that offers exciting promise of curing many debilitating and potentially terminal diseases, such as cystic fibrosis, multiple sclerosis, hemophilia, sickle cell disease, and spinal muscular atrophy.

Gene Therapy

Member $15.00

Non-Member $30.00

Financial Models to Manage Drug Spend of Gene Therapy - Annual Meeting 2019

Contact Hours 1 - Gene therapy techniques offer potential breakthroughs for patients with serious health conditions. They also are associated with significant short-term costs yet hold the promise of long-term savings.

Gene Therapy

Member Free

Non-Member $30.00

Federal and State Legislative and Regulatory Update - Nexus 2018

Contact Hours: 1.5. This must-attend session will bring you timely updates on the latest federal and state legislative and regulatory actions of interest to managed care and specialty pharmacy professionals.

Law

Member Free

Non-Member $30.00

Experience and Lessons Learned in Biosimilar Uptake - Nexus 2018

Contact Hours: 1.5. Although biosimilars have been on the market for some time, payers continue to face many challenges in implementation.

Biosimilars

Member Free

Non-Member $30.00

How Continued Drug Shortages Compromise Patient Care

Contact Hours: 1.5. Providing safe and effective drug therapy has become extremely challenging during extended periods of drug shortages.

Drug Shortages

Main Catalog

Error